The Role of Genetic Factors in the Development of Myocardial Infarction in the Kazakh Population

Asfendiyarov Kazakh National Medical University

Status: Completed

Conditions: Heart Attack

Treatments: Genetic: DNA analysis

Study type: Observational

Funder types: Other

Identifiers

NCT05090618

1187

Details and patient eligibility

About

This is a GWAS study that aims to identify possible candidate genes associate to heart attack by exploring single nucleotide polymorphism (SNP) in a group of heart attack, in the Kazakh population. The investigators hypothesize that the careful phenotyping of the subject sand matching with increase the power to find SNP significantly associate with heart attack

Full description

A genome-wide association study (GWAS) is an approach used in genetics research to associate specific genetic variations with particular diseases. The method involves scanning the genomes from many different people and looking for genetic markers that can be used to predict the presence of a disease. Once such genetic markers are identified, they can be used to understand how genes contribute to the disease and develop better prevention and treatment strategies.

Enrollment: 500 patients

Sex: All

Ages: 18 to 60 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Persons of Kazakh nationality
• Age up to 59 years inclusive at the time of primary myocardial infarction
• Myocardial infarction was established in accordance with the EOC criteria: An increase and / or decrease in the level of cardiac troponin must be combined with at least one of the following: • Symptoms of myocardial ischemia • Newly occurring ischemic changes on the ECG • The appearance of a pathological Q wave • Identification according to imaging data methods of new areas of non-viable myocardium, or new areas of local contractility disorders of presumably ischemic etiology • Detection of a thrombus in the coronary arteries according to coronary angiography
• Presence of coronary angiography
• Persons able and willing to provide written informed consent;

Exclusion criteria

• Age at primary myocardial infarction 60 years and older
• Heart defects, congenital and acquired
• Non-ischemic cardiomyopathies
• Autoimmune diseases
• Diabetes mellitus at the time of development of primary myocardial infarction
• Terminal stages of renal and hepatic failure

Trial design

500 participants in 2 patient groups

Experimental group:

Description:

Patients with Heart Attack

Treatment:

Genetic: DNA analysis

Control group

Description:

Patients without Heart Attack

Treatment:

Genetic: DNA analysis